Therapeutic immunization for the control of HIV-1: where are we now?
Highly active antiretroviral therapy (HAART) has transformed HIV-1 infection from an invariably fatal disease into a chronic infection requiring lifelong treatment. However, the challenges we still face are the urgent need to provide affordable sustainable therapy to the millions of infected individuals who live in resource-poor countries, and the limitations posed by serious drug toxicity and viral resistance associated with long-term therapy. Augmentation of HIV-specific immunity by therapeutic vaccination is a possible alternative to continuous HAART. In this review, progress in the development of therapeutic immunization strategies is discussed.
Dorrell
Lucy
L
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK. ldorrell@gwmail.jr2.ox.ac.uk
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization / Q000379:methods*; D019444:Vaccines, DNA / Q000276:immunology
D016915:AIDS Vaccines; D019444:Vaccines, DNA